OCC Trading, page-1744

My personal belief (as I'm sure many other's on here share), is that'll be the FDA approval early next year that'll be the turning point. (Knowing this company however that approval might be late and run into the second Qtr CY25).


_{^{24 July 2024}}

Revenue will remain choppy into FY25/26 and so we'll still have investors/traders on here whinge & whine when things aren't progressing in an increasing linear fashion, but those with common sense (which seems lacking these days) will be able to see the forest for the trees as more regions/markets become unlocked.


_{^{Company Presentation July 2024}}

And this exludes their SmrtGraft tendon/ligament repair (TGA application back in early June) (alone worth >US$1.2B annually) and ATI product lines too.

SmrtGraft will be the third revenue generating product to be launched by the Company.
_{^{11 June 2024}}

♦ >800,000 surgical repairs of RC tendons alone completed in just the AUS, USA and EU per year.

♦ Multiple tendon applications in addition to the rotator cuff, including tendons in the knee, hip, ankle, elbow, wrist and hands.

♦ Geographical roll-out strategy for tendon and ligament repair devices in progress, starting with Australia and other key regulatory jurisdictions to follow

"The Company believes SmrtGraft will become a leading tendon repair device, with uptake driven by the surgeon’s preference for high quality, easy to use devices that facilitate better patient outcomes. The Company is well-positioned to achieve further international approvals for SmrtGraft in tendon and ligament repair – a key growth area for our business. Planned geographical roll out starts with Australia, with approvals in other key markets to follow."